Olfactory and oral manifestations of COVID-19: Sex related symptoms - a potential pathway to early diagnosis

*Ameen Biadsee MD, *Ameer Biadsee DMD, MHA, Firas Kassem MD, Or Dagan MD, Shchada Masarwa BDS, Zeev Ormianer DMD

*Equal contribution

1Department of Otorhinolaryngology - Head and Neck Surgery, Meir Medical Center, Kfar Saba, Israel
2Department of Oral Rehabilitation, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
3Department of Otorhinolaryngology - Head and Neck Surgery Hillel Yaffe, Medical Center, Hadera, Israel
4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Conflict of interest: The authors have no conflicts of interest to report.

Funding: None.

Ameen Biadsee: Design, conduct and writing

Ameer Biadsee: Design conduct and writing
Firas Kassem: Design and reviewing

Or Dagan: Analysis and writing

Shchada Masarwa: Analysis

Zeev Ormianer: Design and reviewing

Correspondence

Ameen Biadsee, MD.
Department of Otolaryngology - Head and Neck Surgery
Meir Medical Center
59 Tchernichovsky St.
Kfar Saba, 44410
Israel
Tel: +97297472553
Fax: +97297472149
Email: Aminbi@clalit.org.il
Objective The COVID-19 pandemic poses a threat to global health. Early diagnosis is an essential key to limit the outbreak of the virus.

Study Design: Case series, study conducted between March 25, 2020, and April 15, 2020.

Setting: Ambulatory, non-hospitalized patients who were quarantined in a designated hotel for COVID-19 patients and were recruited by an advertisement at the hotel.

Subjects and Methods: One-hundred forty patients participated in a Web-based questionnaire assessing initial symptoms of common viral diseases, olfactory and taste functions, xerostomia and orofacial pain.

Results: A total of 58 men and 70 women participated. Initial symptoms were cough (59.4%), weakness (47.7%), myalgia (46.9%), fever (42.2%), headache (40.6%), impaired sense of smell (38.3%), impaired sense of taste (32.8%), sore throat (26.6%), runny nose (26.6%) and nasal congestion (22.7%). All symptoms were more frequent among women; however, only runny nose was statistically significant ($p=0.018$). The most common combination of symptoms was cough and weakness (37.5%). 25.8% reported olfactory and taste dysfunctions in the absence of other symptoms. In a comparison between the sexes, cough and runny nose were the most common combination in women ($p=0.018$). A total of 38.3% of patients reported olfactory dysfunction as an initial symptom. Anosmia and facial pain were more common among women ($p<0.001$ and $p=0.01$, respectively) and 56% of patients reported xerostomia.

Conclusion: A considerable number of patients presented with olfactory and oral disorders. Interestingly, women presented with a different cluster of symptoms than men, which may suggest a new clinical approach to diagnosing COVID-19 disease.

Keywords: Coronavirus, COVID-19, Anosmia, Xerostomia, Dysgeusia
Introduction

COVID-19 is an infectious disease caused by a newly discovered coronavirus. The causative pathogen was identified as SARS-CoV-2, which is the seventh type of the coronavirus family to affect humans.\textsuperscript{1,2} On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic.

The virus is transmitted from human to human via droplet transmission and direct contact with oral, nasal, and eye mucous membranes.\textsuperscript{3} Studies suggest that COVID-19 may become airborne through aerosols generated during clinical procedures.\textsuperscript{4}

COVID-19 has an incubation period of 1-14 days, with most ranging from 3 to 7 days.\textsuperscript{5} Other studies suggest an incubation period of 5.2 days.\textsuperscript{6} According to the World Health Organization, an acute respiratory infection, fever and cough are the most valid diagnostic clinical features.\textsuperscript{7}

Social isolation has proven effective in avoiding contamination among the population.\textsuperscript{8} Early detection of symptoms is essential. Some common oro-facial manifestations of viral infection may contribute to early diagnosis of COVID-19 infection. Recent reports demonstrated that loss of taste and smell can be the first and only manifestations of infection.\textsuperscript{9,10}

This study assessed early manifestations of COVID-19, with an emphasis on olfactory and oral disorders.
Material and Methods:

The study was conducted in the Department of Oral Rehabilitation, School of Dental Medicine of Tel Aviv University, in collaboration with the Otorhinolaryngology Department, Meir Medical Center (affiliated with Tel Aviv University). The study protocol was approved by the Tel Aviv University Ethics Committee (application number - 000120) with digital consent obtained from all participants.

Participants

According to the Israel Ministry of Health, by April 14, 2020 a total of 9,870 COVID-19 patients were diagnosed in Israel (9,385 ambulatory patients). Among them, 140 ambulatory, non-hospitalized patients who were quarantined in a designated hotel for COVID-19 patients and were recruited by an advertisement at the hotel (sample size 1.42%). All patients were diagnosed by reverse transcription-polymerase chain reaction assay (RT-PCR) and considered to have mild symptoms, according to the latest WHO joint report. A web-based survey tool, Google Forms (Google, LLC) was used to create the questionnaire. A standard digitally secured questionnaire link was sent to each patient’s mobile phone. Patients could submit the questionnaire only once. A digital consent to participate in the study was obtained prior to completing the questionnaire.

The Questionnaire

A questionnaire was designed for this study because most available questionnaires did not include the epidemiological and various possible oral, taste and smell manifestations of COVID-19 infection. The questionnaire contained 6 sections and a total of 31 questions (Appendix A). The first section included demographic data, smoking status and chronic medications use. The second
section contained a multiple-choice question about geographic location of source of infection (Israel, Europe, USA or other) if known, estimated date of exposure, date of the first symptom and date of detection by the Israeli health services. Estimated incubation period was calculated as the number of days between the estimated date of exposure and the date of the first symptom, in order to investigate its effect on different variables. Additionally, a checklist of common symptoms of viral infection, such as cough, fever, myalgia, weakness, sore throat, nasal congestion and rhinorrhea, dysfunction in olfaction and taste, and headache was included. The patient could mark more than one symptom.

Section 3 contained questions regarding oral hygiene. The question, “Has your dentist advised you that you have gum disease” was included to determine whether chronic gingivitis and possible oral bleeding were associated with COVID-19 infection.

Section 4 included oral manifestations. It contained simple dichotomous questions about facial pain, masticatory pain, sense of burning in the oral cavity, change in sensation or swelling in the oral cavity and bleeding. The question, “Do you feel the need to drink more (dry mouth)?” was included to evaluate xerostomia. Pain and burning sensation were estimated using a standard VAS pain scale, with 0 representing no pain and 10 severe pain. Patients were asked to mark the locations of facial and masticatory pain (Fig. 1).

In Section 5, taste was assessed using dichotomous questions about spicy, salty, sour and sweet tastes (taste subgroups). A patient who had experienced a change in any of the tastes was considered to have “taste change”. In section 6, change in smell was evaluated using dichotomous question. “Is your perception of smells distorted since the onset of the infection, if yes, describe?” was used to describe parosmia, phantosmia and cacosmia. Anosmia was defined as a score of zero on the VAS scale. Timing of smell dysfunction was assessed using
a multiple-choice question: phase 1 was defined as the first day of illness, phase 2 as third through fifth days, and phase 3 as after the fifth day.

Subjective smell and taste dysfunctions were measured separately using a metric scale, from 0 to 10. Zero representing anosmia and ageusia and 10 representing a very good sense of smell and taste, respectively. This scale was used to simplify the questionnaire and obtain statistical correlations easily with the VAS scale used with different variables. Information obtained from questionnaires was tallied and summarized.
Statistical analysis

Statistical data and figures were analyzed using R project for statistical computing, version 3.6.2 (2019-12-12). Reported measures were tested for association with the demographic variables as follows: sex (man/woman), smoker (yes/no), geographic location of infection (Israel, etc.), incubation period (less/more than 5.2 days) and interactions between the latter two. For dichotomous variables such as symptoms (yes/no), their prevalence was fitted in correspondence using logistic regression. Otherwise, linear regression was used. The statistical significance of each covariate was tested using the Likelihood Ratio Test.

Correlations between the 11 possible symptoms were analyzed using Wilks test.

Concurrences of any combination of symptoms were further explored with a Venn Diagram.

The prevalence among men compared to women were tested using Fisher’s Odds Ratio (OR).

All tests and credible intervals are reported at a level of $\alpha = 5\%$.

Correlation between symptoms

A total of 88 unique combinations of symptoms were reported in the sample. Using Wilk’s $\chi^2$ statistic, we quantified the extent of dependence between the 11 symptoms at once, where

$$\chi^2 = 651 \text{ with } df = 88, P = P_{\chi^2 88 \geq 651} < 10^{-5}$$

indicating extreme dependence.
Results

Twelve of 140 questionnaires were excluded due to missing information. A total of 58 men and 70 women were included in the study.

Demographic and epidemiological data and initial symptoms are listed in Table 1.

Table 1. Demonstrates demographic, epidemiological data and initial symptoms. *Most patients reported more than one initial symptom.

1 Due to insufficient information, this parameter was not included in data analysis.

2 Runny nose was statistically different between the sexes. (P = 0.018).

Figure 2 illustrates the 60 most prevalent combinations of symptoms among all patients. The most common combinations were cough and weakness (37.5%), cough and myalgia (32%), and myalgia and weakness (30.5%). The top panel shows the corresponding p-values for comparisons between men and women.

Figure 3 illustrates the 23 significant combinations of symptoms between sexes. Cough and runny nose were the most prevalent and significant combination (p=0.018). It is worth noting that weakness was described in 14 of the 23 most prevalent combinations.

Olfactory dysfunction

Eighty-six (67%) patients reported olfactory dysfunction during the disease (35 men, 51 women) and 19.5% reported anosmia, which was more frequent among women (p<0.001).

Mean smell scores after the onset of the disease were significantly lower among women (p=0.04). Olfactory dysfunction was more common during the third through fifth days of the illness, with no statistical difference between the sexes.
Significant correlations between smell dysfunction, taste dysfunction and taste subgroups and smell dysfunction were found \( (p<0.001) \). Nasal congestion strongly correlated with smell dysfunction \( (p=0.01) \). However, no correlation with anosmia was demonstrated.

**Taste**

Sixty-seven patients (52%) reported changes in taste sensation. 52 patients reported a change in their spicy taste perception, 54 in salty taste, 53 in sour taste and 61 sweet taste. In a comparison between men and women, taste change and change in taste subgroups were more common among women, with no significant statistical difference.

Mean scores of taste perception before onset of the disease were higher among women \( (p=0.02) \).

**Dry Mouth**

Seventy-two patients reported dry mouth (28 men, 44 women) and a strong association with burning mouth and taste change was found \( (p=0.002, p=0.009, \text{respectively}) \). However, no correlation with any of taste subgroups, rhinorrhea or nasal congestion was found.

**Facial pain**

Facial pain was more common among women \( (p=0.01) \), as 18 (26%) reported facial pain, particularly in location 5 (forehead), with mean VAS score of 5 (Fig. 1).

A significant correlation was found between facial pain and nasal congestion \( (p=0.001) \). This relation was significant in location 5 \( (p=0.01) \). There was no correlation between facial pain and headache \( (p=0.08) \). However, a significant correlation was found between facial pain in location 5 and headache \( (p=0.02, r=0.469) \).
Masticatory muscle pain

Fifteen patients reported muscle pain during mastication (11%), with a mean VAS score of 3.8. Nine patients noted that the pain was in location 3, 7 in locations 1 and 4, and 6 in location 2 (Fig. 1).

A significant correlation between masticatory and facial pain (p<0.001, r=0.652) was found.

Additional oral manifestations

Twenty patients reported change in sensation in the tongue, 9 patients reported plaque-like changes in the tongue. Ten patients reported swelling the oral cavity; 4 in the palate, 4 in the tongue and 2 in the gums.

Change in tongue sensation strongly correlated with swollen palate and plaque-like changes in the tongue. (p<0.001).

Six patients reported current oral bleeding, 3 of whom reported past bleeding. No spontaneous bleeding reported.

Oral hygiene

Oral hygiene was not correlated with any of the variables.
Discussion

General symptoms

Corona viruses are the second most common cause of viral URTI in adults, as well as upper and lower respiratory, and systemic symptoms.\textsuperscript{13,14} Previous studies on the symptoms caused by common cold viruses failed to identify the virus based on clinical symptoms, because viral infections \textit{per se} does not generate symptoms; rather, the host’s immune system.\textsuperscript{15,16}

Figure 2. Illustrates the 60 most common combination of symptoms among mild COVID-19 patients. Similar to a recently published cohort study, we found that cough, weakness and myalgia were the most prevalent symptoms.\textsuperscript{17} We found 23 significant combination of symptoms when comparing men and women (Fig 3). These findings are substantially important, because men might have fewer symptoms. An increased level of awareness and caution among health personnel, when addressing an asymptomatic patient is mandatory.

Olfactory dysfunction

Viral URTI is one of the most commonly identified causes of olfactory dysfunction.\textsuperscript{14,18} Olfactory impairments can be classified into conductive losses stemming from obstruction of the nasal passages, and sensorineural causes from damage to the olfactory neuroepithelium, which is most often attributed to post-viral olfactory loss.\textsuperscript{14,19,20} Mao et al. reported the presence of neurologic manifestations among COVID-19 patients who were hospitalized in Wuhan, China in 2019. Smell and taste impairment were the most frequently reported peripheral nerve symptoms. These findings were elucidated based on the known ability of SARS and MERS viruses to enter the CNS through a retrograde neuronal route.\textsuperscript{21} Since then, several reports have described the same phenomena.\textsuperscript{22,23} Kay et al. reported anosmia as the first symptom among more than approximately 25\% of COVID-19 patients.\textsuperscript{24} Consistent with
previous studies, in the current study, 38.3% reported olfactory dysfunction as the first symptom and 66% reported the presence of olfactory dysfunction during the ailment period.

In an effort to find the driving factor for the high prevalence of olfactory dysfunction, we found it significantly correlated with nasal congestion. This implies that obstructed nasal passages might have served as a significant component of the olfactory impairment. Nevertheless, it is worth mentioning that we found no correlation between nasal congestion and anosmia. It is possible that damage to the olfactory neuroepithelium had a meaningful contribution to anosmia.

True loss of taste is extremely rare and it is usually preceded by the inability to perceive the odor of food due to olfactory dysfunction. In this analysis, 25.8% reported an impaired sense of smell with impaired sense of taste in the absence of other symptoms. we believe that these results may point out the need to examine and isolate patients with olfactory and taste impairment in order to reduce the COVID-19 infection rate.

Xerostomia

Taste is the main stimulant for saliva formation. In our cohort, more than 50% of patients reported dysgeusia and xerostomia, which were significantly correlated, supporting this mechanism. Previous studies showed that xerostomia is secondary to nasal congestion and rhinorrhea due to mouth breathing. However, there was no significant correlation between dysgeusia and nasal congestion or xerostomia with nasal congestion and rhinorrhea. This condition may be explained by olfactory dysfunction or may suggest neurological involvement that may lead to dysgeusia and xerostomia. Interestingly, we found no significant difference in xerostomia between men and women, this contradicts previous studies in the literature.27,28
A common manifestation of xerostomia is a burning sensation, which was demonstrated in this present study and confirmed in previous studies.  

Facial pain

Our findings are in agreement with a number of studies showing that facial pain is more common in women than men.  Moreover, a strong correlation between pain in the forehead and headache was found, which can be explained by the patients’ inability to differentiate between headache and facial pain the forehead. Facial pain was associated with nasal congestion, because nasal congestion occurs during URTI as a result of dilatation of veins in the nasal epithelium, adding to the accumulation of secretions in the sinuses. This leads to pressure changes, eventually stimulating adherent trigeminal nerve endings, causing a pain sensation.

Limitations

This study was limited by the small sample size. In addition, some data were missing, including information on comorbidities.
Conclusion

SARS-COV-2 may manifest with various combinations of symptoms. General symptoms as cough and weakness (37.5%), cough and myalgia (32%), myalgia and weakness (30.5%) were the most common combination of symptoms. This study may provide new clinical information that could increase the ability to diagnose COVID-19 patients sooner. It is especially meaningful to learn about differences between sexes, as cough and runny nose were significantly more common among women than among men. It is important to notice the high proportion of patients who presented only with impaired sense of smell and taste.

Acknowledgments: We thank Ms. Eiman Jaljole, M.Sc. for her role in statistical analysis.
References


22. COVID-19 Outbreak. WORLD SCIENTIFIC; 2020. doi:10.1142/11827


Figure legends:

Figure 1. Pain locations (Facial and masticatory muscle pain)

(A) Facial pain (B) Left side masticatory muscle pain (C) Right side masticatory muscle pain.
Figure 2. Combinations of initial symptoms.

The grid in the lower part maps the combination of symptoms examined (x-axis), the corresponding value on y-axis is the overall prevalence in the sample (black solid line), prevalence among men (blue dot-dashed line) and prevalence among women (red dashed line). The upper panel reports Fisher’s Odds Ratio test for the null odds ratio of men vs. women is 1. For example, the far left column shows the prevalence of patients who experienced both cough and weakness: ≈ 35% overall, ≈ 33% of the women and ≈ 41% of the men. Odds ratio with P ≈ 0.4. Sixty most frequent combinations are displayed; in 5 combinations women had significantly increased odds compared to men with P<0.05 (grey vertical lines).
Figure 3. Twenty-three symptom combinations with significant Odds Ratio (P<.05) between men and women.

The 128 patients reported 88 unique combinations of symptoms; in 23 there was a significant difference in Odds between women and men. The corresponding p-values are annotated and aligned with each combination.
Table 1. Demonstrates demographic, epidemiological data and initial symptoms.

<table>
<thead>
<tr>
<th>Category</th>
<th>Mean (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>36.25 years (18-73)</td>
</tr>
<tr>
<td>Incubation period</td>
<td>4.6 days (1-13)</td>
</tr>
<tr>
<td>Smoking</td>
<td>n (%)</td>
</tr>
<tr>
<td>Chronic illnesses† (n=17)</td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>4 (3%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>8 (6%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>3 (2%)</td>
</tr>
<tr>
<td>Country of infection (n=128)</td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td>94 (73%)</td>
</tr>
<tr>
<td>EU</td>
<td>18 (14%)</td>
</tr>
<tr>
<td>USA</td>
<td>12 (9%)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (2%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (2%)</td>
</tr>
<tr>
<td>Initial symptoms‡</td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>Men 30 (51%)</td>
</tr>
<tr>
<td></td>
<td>Women 64 (66%)</td>
</tr>
<tr>
<td></td>
<td>Total 94 (59%)</td>
</tr>
<tr>
<td>Weakness</td>
<td>Men 25 (42%)</td>
</tr>
<tr>
<td></td>
<td>Women 36 (51%)</td>
</tr>
<tr>
<td></td>
<td>Total 61 (48%)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>Men 27 (46%)</td>
</tr>
<tr>
<td></td>
<td>Women 33 (47%)</td>
</tr>
<tr>
<td></td>
<td>Total 60 (47%)</td>
</tr>
<tr>
<td>Fever</td>
<td>Men 24 (41%)</td>
</tr>
<tr>
<td></td>
<td>Women 30 (43%)</td>
</tr>
<tr>
<td></td>
<td>Total 54 (42%)</td>
</tr>
<tr>
<td>Headache</td>
<td>Men 21 (36%)</td>
</tr>
<tr>
<td></td>
<td>Women 31 (44%)</td>
</tr>
<tr>
<td></td>
<td>Total 52 (40%)</td>
</tr>
<tr>
<td>Impaired sense of smell</td>
<td>Men 22 (38%)</td>
</tr>
<tr>
<td></td>
<td>Women 27 (38%)</td>
</tr>
<tr>
<td></td>
<td>Total 49 (38%)</td>
</tr>
<tr>
<td>Impaired sense of taste</td>
<td>Men 16 (27%)</td>
</tr>
<tr>
<td></td>
<td>Women 26 (37%)</td>
</tr>
<tr>
<td></td>
<td>Total 42 (32%)</td>
</tr>
<tr>
<td>Sore throat</td>
<td>Men 10 (17%)</td>
</tr>
<tr>
<td></td>
<td>Women 24 (34%)</td>
</tr>
<tr>
<td></td>
<td>Total 34 (26%)</td>
</tr>
<tr>
<td>Runny nose*</td>
<td>Men 9 (15%)</td>
</tr>
<tr>
<td></td>
<td>Women 25 (35%)</td>
</tr>
<tr>
<td></td>
<td>Total 34 (26%)</td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>Men 9 (15%)</td>
</tr>
<tr>
<td></td>
<td>Women 20 (28%)</td>
</tr>
<tr>
<td></td>
<td>Total 29 (22%)</td>
</tr>
<tr>
<td>Gastro-intestinal symptoms</td>
<td>Men 6 (10%)</td>
</tr>
<tr>
<td></td>
<td>Women 18 (25%)</td>
</tr>
<tr>
<td></td>
<td>Total 24 (19%)</td>
</tr>
</tbody>
</table>

Table 1. Demonstrates demographic, epidemiological data and initial symptoms.

† Due to insufficient information this parameter was not included in statistical analysis.

‡ Most patients reported more than one initial symptom.

* Runny nose was statistically different between the sexes. (p=0.018).
Figure 1. Pain locations (Facial and masticatory muscle pain)

(A) Facial pain (B) Left side masticatory muscle pain (C) Right side masticatory muscle pain
Figure 2

Impaired Sense of Smell
Runny Nose
Sore Throat
Headache
Nausea
Myalgia

Set size
Gender
Men
Women
Any

This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery.
Cough
Weakness
Myalgia
Fever
Headache
Impaired Sense of Smell
Impaired Sense of Taste
Runny Nose
Sore Throat
Nasal Congestion
Nausea

Estimated Prevalence

Gender
Any
Women
Men

pv = 0.018
pv = 0.047
pv = 0.04
pv = 0.034
pv = 0.034
pv = 0.034
pv = 0.034
pv = 0.034
pv = 0.02
pv = 0.034
pv = 0.034
pv = 0.034
pv = 0.034
pv = 0.034
pv = 0.02
pv = 0.034
pv = 0.034
pv = 0.034
pv = 0.034
pv = 0.025
pv = 0.025
pv = 0.025
pv = 0.042
pv = 0.042
pv = 0.042
pv = 0.042
pv = 0.031
pv = 0.031
pv = 0.031
pv = 0.031
pv = 0.037
pv = 0.037
pv = 0.037
Appendix A. Study questionnaire

Section 1. Personal information

1. Age

1.1. Sex

1.2. Mobile phone

1.3. Do you currently smoke?
   a. Yes
   b. No

1.4. Do you have any chronic illnesses?
   If yes, please note:

1.5. Do you take any medications on daily basis?
   If yes, please note:

Section 2. COVID-19 epidemiology

2. Country of infection
   a. Israel
   b. Europe
   c. USA
   d. Other

3. Date of detection

4. Do you know when you were exposed to COVID-19:

5. When did first symptom appear:

6. What was the first symptom (can be more than one)
   a. Cough
b. Fever  
c. Muscle pain  
d. Runny nose  
e. Stuffed nose  
f. General weakness  
g. Sense of taste affected  
h. Sense of smell affected  
i. Headaches  
j. Nausea/Vomiting/Diarrhea  
k. Sore throat  

**Section 3. Oral hygiene**

7. how many times a day, do you brush your teeth:  

8. How many times a day, do you use mouthwash:  

9. How many times a day, do you use dental floss:  

10. Do you use any other dental products (Water jet, brushes between teeth, etc.)

11. How often do you visit dental hygienist (in months):  

12. Has your dentist advised you, that you have gum disease?  

   Explain what you were told:  

**Section 4. Clinical Oral Manifestation**

4.1 Facial pain  

13. Do you have facial pain?  

   a. Yes  

   b. No  

13.1. If yes, what is the severity on a scale from 0 to 10? **  

13.2. If yes, note down numbered areas: (Figure 1.A)
13.3. Have you felt facial pain before COVID-19 onset, if yes how many days before:

4.2 Masticatory muscle pain

14. Do you have facial and masticatory muscle pain?
   a. Yes
   b. No

14.1. If yes, what is the severity on a scale from 0 to 10? **

14.2 If yes, note down numbered areas (Figure 1.C for the right side and figure 1.B for the left side):

14.3. Have you felt facial and masticatory muscle pain before COVID-19 onset, if yes how many days before?

4.3 Oral cavity

15. Have you experienced any change of sensation in:
   a. Tongue
   b. Cheeks
   c. Gums
   d. I do not feel any change of sensation

15.1. Have you felt change of sensation before COVID-19 onset, if yes how many days before?

16. Are you experiencing any swelling in your mouth?
   1. Gums 2. Tongue 3. Palate 4. I have no swelling

16.1. Have you felt this swelling before COVID-19 onset, if yes how many days before?

17. Have you noticed any changes in your cheeks or tongue?
   a. Yes
   b. No
17.1. If Yes, note the changes (color, swelling, texture etc.)

18. Do you have any bleeding in your mouth since COVID-19 onset?
   a. Yes
   b. No

18.1. If yes, did the exist previously, lately?
   a. Yes
   b. No

18.2. If yes, when does it occur?
   a. When brushing
   b. Spontaneously

19. Do you feel the need to drink more (dry mouth)?
   a. Yes
   b. No

19.1. Have you felt the need to drink more (dry mouth) before COVID-19 onset, if yes how many days before?

20. Are you experiencing a burning sensation in your mouth:
   a. Yes
   b. No

20.1. If yes, what is the severity on a scale from 0 to 10?

20.2. Have you felt this sensation before COVID-19 onset, if yes how many days before?

**Section 5. Taste**

21. Do you feel a change in your sense of taste- Spicy?

22. Do you feel a change in your sense of taste- salty?

23. Do you feel a change in your sense of taste-sour?
24. Do you feel a change in your sense of taste- sweet?
25. Have you felt these changes before COVID-19 onset, If yes how many days before:
26. Rate your usual sense of taste in general, on a scale from 0 to 10
27. Rate your sense of taste to date, on a scale from 0 to 10

**Section 6. Smell**

28. Have you noticed a change in your sense of smell since COVID-19 onset?
   a. Yes
   b. No

29.1. Is your perception of smells distorted since COVID-19 onset, if yes describe?
29.2. If your sense of smell has changed, since when?
   a. On the first day of illness
   b. Between days 3-5
   c. After day 5

30. Rate your usual sense of smell in general, on a scale from 0 to 10:

31. Rate your sense of taste to date, on a scale from 0 to 10: